GRAIL (GRAL) Competitors

GRAIL logo
$105.60 -10.29 (-8.88%)
Closing price 04:00 PM Eastern
Extended Trading
$107.00 +1.40 (+1.33%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAL vs. INCY, INSM, BNTX, ALNY, and EXEL

Should you buy GRAIL stock or one of its competitors? GRAIL's main competitors and comparable companies include Incyte (INCY), Insmed (INSM), BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY), and Exelixis (EXEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GRAIL compare to Incyte?

Incyte (NASDAQ:INCY) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Incyte has a net margin of 6.71% compared to GRAIL's net margin of -243.80%. Incyte's return on equity of 7.92% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte6.71% 7.92% 6.12%
GRAIL -243.80%-16.13%-14.38%

Incyte has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market.

In the previous week, Incyte had 10 more articles in the media than GRAIL. MarketBeat recorded 18 mentions for Incyte and 8 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Incyte's score of 0.45 indicating that GRAIL is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Incyte currently has a consensus target price of $132.86, suggesting a potential upside of 9.83%. GRAIL has a consensus target price of $128.80, suggesting a potential upside of 11.14%. Given GRAIL's higher possible upside, analysts plainly believe GRAIL is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

Incyte has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$6.01B4.10$1.29B$1.8864.35
GRAIL$166.60M31.28-$408.35M-$9.50N/A

Summary

Incyte beats GRAIL on 12 of the 16 factors compared between the two stocks.

How does GRAIL compare to Insmed?

GRAIL (NASDAQ:GRAL) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

GRAIL has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Insmed has a net margin of -39.85% compared to GRAIL's net margin of -243.80%. GRAIL's return on equity of -16.13% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
Insmed -39.85%-96.38%-32.55%

GRAIL has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$166.60M31.28-$408.35M-$9.50N/A
Insmed$606.42M43.83-$1.28B-$2.82N/A

GRAIL currently has a consensus price target of $128.80, suggesting a potential upside of 11.14%. Insmed has a consensus price target of $196.52, suggesting a potential upside of 62.20%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

In the previous week, GRAIL and GRAIL both had 8 articles in the media. Insmed's average media sentiment score of 1.17 beat GRAIL's score of 0.60 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Insmed beats GRAIL on 9 of the 13 factors compared between the two stocks.

How does GRAIL compare to BioNTech?

GRAIL (NASDAQ:GRAL) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, BioNTech had 1 more articles in the media than GRAIL. MarketBeat recorded 9 mentions for BioNTech and 8 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat BioNTech's score of 0.38 indicating that GRAIL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

15.5% of BioNTech shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GRAIL has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

GRAIL currently has a consensus price target of $128.80, suggesting a potential upside of 11.14%. BioNTech has a consensus price target of $122.27, suggesting a potential upside of 42.83%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
BioNTech
1 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.68

BioNTech has a net margin of -61.39% compared to GRAIL's net margin of -243.80%. BioNTech's return on equity of -4.51% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
BioNTech -61.39%-4.51%-3.96%

GRAIL has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$166.60M31.28-$408.35M-$9.50N/A
BioNTech$2.42B8.94-$1.29B-$6.85N/A

Summary

BioNTech beats GRAIL on 12 of the 17 factors compared between the two stocks.

How does GRAIL compare to Alnylam Pharmaceuticals?

GRAIL (NASDAQ:GRAL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than GRAIL. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 8 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Alnylam Pharmaceuticals' score of 0.37 indicating that GRAIL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Alnylam Pharmaceuticals
1 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alnylam Pharmaceuticals has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$147.17M32.26-$408.35M-$9.50N/A
Alnylam Pharmaceuticals$3.71B5.76$313.75M$19.268.29

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to GRAIL's net margin of -243.80%. Alnylam Pharmaceuticals' return on equity of 155.33% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
Alnylam Pharmaceuticals 52.85%155.33%44.81%

GRAIL has a beta of 2.86, indicating that its share price is 186% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

GRAIL presently has a consensus target price of $128.80, suggesting a potential upside of 21.97%. Alnylam Pharmaceuticals has a consensus target price of $305.86, suggesting a potential upside of 91.49%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Alnylam Pharmaceuticals beats GRAIL on 12 of the 16 factors compared between the two stocks.

How does GRAIL compare to Exelixis?

GRAIL (NASDAQ:GRAL) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Exelixis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GRAIL$166.60M31.28-$408.35M-$9.50N/A
Exelixis$2.50B6.74$782.57M$3.3420.66

Exelixis has a net margin of 35.45% compared to GRAIL's net margin of -243.80%. Exelixis' return on equity of 45.54% beat GRAIL's return on equity.

Company Net Margins Return on Equity Return on Assets
GRAIL-243.80% -16.13% -14.38%
Exelixis 35.45%45.54%33.90%

85.3% of Exelixis shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Exelixis had 7 more articles in the media than GRAIL. MarketBeat recorded 15 mentions for Exelixis and 8 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Exelixis' score of 0.46 indicating that GRAIL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GRAIL
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Exelixis
4 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

GRAIL has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

GRAIL presently has a consensus price target of $128.80, indicating a potential upside of 11.14%. Exelixis has a consensus price target of $58.62, indicating a potential downside of 15.05%. Given GRAIL's higher probable upside, analysts plainly believe GRAIL is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Exelixis
1 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.39

Summary

Exelixis beats GRAIL on 13 of the 17 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRAL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRAL vs. The Competition

MetricGRAILBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.46B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E RatioN/A24.2434.3430.11
Price / Sales32.2614.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book1.944.354.763.85
Net Income-$408.35M-$24.19M$3.52B$393.14M
7 Day Performance-17.55%-7.26%-5.34%-4.53%
1 Month Performance-10.36%-4.96%-3.61%-5.86%
1 Year Performance32.61%-2.87%0.01%-7.78%

GRAIL Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRAL
GRAIL
2.5321 of 5 stars
$105.60
-8.9%
$128.80
+22.0%
+45.5%$5.46B$147.17MN/A910
INCY
Incyte
2.9477 of 5 stars
$121.89
+1.9%
$132.86
+9.0%
+16.1%$25.04B$5.14B64.842,844
INSM
Insmed
3.3329 of 5 stars
$116.10
+1.5%
$196.52
+69.3%
-37.3%$24.13B$606.42MN/A1,664
BNTX
BioNTech
3.9931 of 5 stars
$87.51
flat
$122.27
+39.7%
-17.0%$22.94B$3.25BN/A7,807
ALNY
Alnylam Pharmaceuticals
4.8655 of 5 stars
$156.61
+0.4%
$305.86
+95.3%
-63.3%$20.89B$5.01B8.132,770

Related Companies and Tools


This page (NASDAQ:GRAL) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners